Clarivate Plc, a global leader in connecting people and organizations to intelligence they can trust to transform their world, released its new report, Biopharma Dealmaking in 2023.
Ochre Bio, an innovator in chronic liver disease medicine development, announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors.
Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors Read More »
Royal Philips, a global leader in health technology, announced the launch of the Philips CT 3500, a new high-throughput CT system targeting the needs of routine radiology and high-volume screening programs.
Genentech, a member of the Roche Group, announced positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis.
Roche announced that it will be showcasing innovative laboratory solutions and digital diagnostics through – “Innovation Past, Present and Future” at this year’s WorldLab-EuroMedLab 2023 in Rome, Italy, 21-25 May.
CEO Johan Löf and CFO Henrik Bergentoft will present RaySearch’s interim report for January-March 2023 at a webcast to be held in English on Wednesday, May 17, 2023 at 10:00-10:30 a.m. CEST.
RaySearch Laboratories: Interim report January 1 – March 31, 2023 Read More »
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, announced that it had won an award from the U.S. Defense Innovation Unit, a division of the U.S. Department of Defense, for ‘Exhaled Breath Diagnostics’.
BioArctic AB’s partner Eisai announced the publication of results from a simulation study evaluating the societal value of lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease, in the context of the Japanese health care system in the peer-reviewed journal Neurology and Therapy.
Societal value of lecanemab in Japan published in Neurology and Therapy Read More »
Pfizer Inc. announced the pricing of a debt offering consisting of eight tranches of notes.
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes on May 12, 2023, and the Company has been selected as a constituent of the MSCI China Small Cap Index, with effect from the close of market on May 31,
Inclusion of Recbio In the MSCI China Small Cap Index Read More »
